Ann: PXS Commences Final Cohort Dosing in Phase 1c Cancer Trial, page-2

'An effective pan‐LOX inhibitor for myelofibrosis would open a market that is conservatively estimated at US$1 billion per annum.'

'While Pharmaxis’ primary focus is the development of PXS‐5505 for myelofibrosis, the drug also has potential in several other cancers including liver and pancreatic cancer where it aims to breakdown the fibrotic tissue in the tumour and enhance the effect of chemotherapy treatment.'

Add

Other drugs in development include:

1. PXS-5382 (LOXL2 inhibitor) – anti fibrotic drug for CKD, IPF, NASH
2. PXS-6302 (topical pan LOX inhibitor) - anti fibrotic drug for skin scarring including burns, established scars, and keloids
3. PXS-4699 (dual SSAO/MAOB inhibitor) – anti inflammatory drug for muscular dystrophies such as DMDPXS-4728 (SSAO inhibitor) - anti inflammatory drug being evaluated for neuro inflammatory diseases.
4. PXS-5370 (dual SSAO/MPO inhibitor) - anti inflammatory drug for multiple indications.

The imagination runs wild with the sp doesn't it!

carpe diem!